-
Je něco špatně v tomto záznamu ?
Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis
V. Rehácek, M. Bláha, H. Jirousová, J. Cernohorská, P. Papousek
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
Digitální knihovna NLK
Plný text - Článek
Číslo
Ročník
Zdroj
Zdroj
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2012-06-01
ROAD: Directory of Open Access Scholarly Resources
od 1997
- MeSH
- dospělí MeSH
- hematokrit MeSH
- hemochromatóza krev genetika terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- objem erytrocytu MeSH
- senioři MeSH
- separace krevních složek * MeSH
- transferin analýza MeSH
- transfuze erytrocytů * MeSH
- železo krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive cases of HH were included in a periodic EA program. METHODS AND PATIENTS: EA were performed using a discontinuous flow cell separators. The protocol consisted of a bimonthly EA until normalization of the serum ferritin was reached. The aim was to reduce the total erythrocyte volume by 25-35%, eventually, to adjust the amount so that hematocrit would not drop below 0.25. RESULTS: 530 +/- 101 ml of erythrocytes were removed (median 517, range 116-761 ml). Iron depletion (ferritin < 20 microg/l) was achieved in all patients after a mean 6.9 +/- 7.6 months, median 5 months, range 1-36 months and a mean 14 EA sessions. The procedures were well tolerated and there were no severe side-effects. CONCLUSIONS: We conclude that HH patients treated with EA achieved iron depletion quickly under good conditions of tolerance. The efficacy, speed, tolerability, and more favorable schedule of an EA program facilitate treatment of HH.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13037648
- 003
- CZ-PrNML
- 005
- 20131129100512.0
- 007
- ta
- 008
- 131126s2012 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/18059694.2015.43 $2 doi
- 035 __
- $a (PubMed)23631289
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Řeháček, Vít $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0103850
- 245 10
- $a Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis / $c V. Rehácek, M. Bláha, H. Jirousová, J. Cernohorská, P. Papousek
- 520 9_
- $a BACKGROUND: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive cases of HH were included in a periodic EA program. METHODS AND PATIENTS: EA were performed using a discontinuous flow cell separators. The protocol consisted of a bimonthly EA until normalization of the serum ferritin was reached. The aim was to reduce the total erythrocyte volume by 25-35%, eventually, to adjust the amount so that hematocrit would not drop below 0.25. RESULTS: 530 +/- 101 ml of erythrocytes were removed (median 517, range 116-761 ml). Iron depletion (ferritin < 20 microg/l) was achieved in all patients after a mean 6.9 +/- 7.6 months, median 5 months, range 1-36 months and a mean 14 EA sessions. The procedures were well tolerated and there were no severe side-effects. CONCLUSIONS: We conclude that HH patients treated with EA achieved iron depletion quickly under good conditions of tolerance. The efficacy, speed, tolerability, and more favorable schedule of an EA program facilitate treatment of HH.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a separace krevních složek $7 D001781
- 650 12
- $a transfuze erytrocytů $7 D017707
- 650 _2
- $a objem erytrocytu $7 D004911
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hematokrit $7 D006400
- 650 _2
- $a hemochromatóza $x krev $x genetika $x terapie $7 D006432
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a železo $x krev $7 D007501
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a transferin $x analýza $7 D014168
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bláha, Milan, $u 4th Department of Medicine, Hematology, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Králové $d 1938- $7 xx0034440
- 700 1#
- $a Jiroušová, Hana $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0301946
- 700 1#
- $a Černohorská, Jitka $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0231605
- 700 1_
- $a Papoušek, Petr $u Transfusion Department Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové $7 xx0108125
- 773 0_
- $w MED00010947 $t Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové $x 1211-4286 $g Roč. 55, č. 4 (2012), s. 180-185
- 856 41
- $u https://actamedica.lfhk.cuni.cz/media/pdf/am_2012055040180.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 3077 $c 1072 $y a $z 0
- 990 __
- $a 20131126 $b ABA008
- 991 __
- $a 20131129100900 $b ABA008
- 999 __
- $a ok $b bmc $g 1002271 $s 836138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 55 $c 4 $d 180-185 $i 1211-4286 $m Acta Medica $n Acta Med. (Hradec Král.) $x MED00010947
- LZP __
- $b NLK111 $a Pubmed-20131126